2. Gihan E-H Gawish, MSc, PhD Ass. Professor Molecular Genetics and Clinical Biochemistry Molecular Genetics and Clinical BiochemistryKSU FIFTH WEEK

3. Purine metabolism (Overview) 1.Nomenclature/nucleotide structure 2.Extracellular Hydrolysis of Ingested Nucleic Acid 3. De novo synthesis pathways 4. Re-utilization pathways 5. Metabolic diseases of purine Metabolism (Gout, Lesch-Nyhan, SCID)

5. DNA RNA 1- Endonucleases Oligonucleotides 2-Phosphodiesterase Nucleotides Ribose + Free Bases 3- Phosphorylase

7. Adenosine Monophosphate Adenine Adenosine The nomenclature of purines depends on their linkage to a pentose Base Nucleotide Base (P0 4 ester) Nucleoside* Base * when the base is purine, then the nucleoside ends in OSINE (AdenOSINE, GuanOSINE, InOSINE)

8. The active forms of nucleotides in biosynthesis and energy conversions are di-and tri-phosphates The active forms of nucleotides in biosynthesis and energy conversions are di-and tri-phosphates CMP + ATP CDP + ADP Nucleoside Monophosphate Kinase XDP + YTP XTP + YDP Nucleoside Diphosphate Kinase (i) (ii)

9. Structures of Common Purine Bases. A= 6 amino purine G= 2 amino, 6-oxy purine A= 6 amino purine G= 2 amino, 6-oxy purine H= 6 oxy purine X= 2,6 dioxy purine H= 6 oxy purine X= 2,6 dioxy purine

10. Aspartate Glutamine (N source) The common mechanistic them for the conversion of A and G is the conversion of a carbonyl oxygen to an amino group Hypoxanthine is an intermediate for Adenine and Guanine

11. There are two basic mechanisms to generate purines and pyrimidines There are two basic mechanisms to generate purines and pyrimidines 2. SALVAGE PATHWAYS (the reutilization of bases from dietary or catabolic sources) 1. DE NOVO BIOSYNTHETIC PATHWAYS (building the bases from simple building blocks)

12. The biosynthesis of purine (A and G) begins with the synthesis of the ribose-phosphate The biosynthesis of purine (A and G) begins with the synthesis of the ribose-phosphate Ribose phosphate pyrophospho-KINASE Pentose phosphate pathway Pentose phosphate pathway

13. The major regulatory step in purine biosynthesis is the conversion of PRPP to 5-Phosphoribosyl-1-amine The major regulatory step in purine biosynthesis is the conversion of PRPP to 5-Phosphoribosyl-1-amine PRPP Glutamine Glutamate PPi Amidophosphoribosyl transferase * Amidophosphoribosyl transferase is an important regulatory enzyme in purine biosynthesis. It is strongly inhibited by the end products IMP, AMP, and GMP. This type of inhibition is called FEEDBACK INHIBITION. Amidophosphoribosyl transferase is an important regulatory enzyme in purine biosynthesis. It is strongly inhibited by the end products IMP, AMP, and GMP. This type of inhibition is called FEEDBACK INHIBITION.

14. Several amino acids are utilized in purine biosynthesis IMP is the precursor for both AMP and GMP, the base is also called hypoxanthine

16. Conversion of Hypoxanthine to Adenine/Guanine. Conversion of Hypoxanthine to Adenine/Guanine. Aspartate Glutamine (N source) The common mechanistic theme for the conversion of A and G is the conversion of a carbonyl oxygen to an amino group The common mechanistic theme for the conversion of A and G is the conversion of a carbonyl oxygen to an amino group

17. Purines: where do the atoms come from? Purine intermediates include: 1. Glycine 2. 1 C units of 5,10 mTHF 3. Glutamine 4. Asparate Purine intermediates include: 1. Glycine 2. 1 C units of 5,10 mTHF 3. Glutamine 4. Asparate

18. Ribose 5-phosphate PRPP Phosphoribosyl amine IMP AMP GMP Inhibited by IMP, AMP, and GMP Inhibited by AMP Inhibited by GMP The regulation of purine biosynthesis is a classic example of negative feedback The regulation of purine biosynthesis is a classic example of negative feedback

19. Endonuclease Phosphodiesterase Nucleoside monophosphates (Mononucleosides) Nucleoside triphosphate Nucleic Acid Synthesis Stages of nucleotide metabolism

20. Endonuclease Phosphodiesterase Nucleoside monophosphates (Mononucleosides) Nucleoside triphosphate Nucleic Acid Synthesis H20H20 Pi Nucleosides Nucleotidases Phosphorylases Pi Ribose-1-P Nucleobases Uric Acid (purines) Nucleoside kinase ATP ADP Phosphoribosyl transferases PRPP PPi

21. Salvage pathways for the re-utilization of purines; There are 2 salvage enzymes with different specificity; 1. Adenine phosphoribosyl transferase 2. Hypoxanthine-guanine phosphoribosyl transferase Salvage pathways for the re-utilization of purines; There are 2 salvage enzymes with different specificity; 1. Adenine phosphoribosyl transferase 2. Hypoxanthine-guanine phosphoribosyl transferase PRPP + AdenineAdenylate PRPP + GuanineGuanylate A-PRT HG-PRT O P OH O O CH 2 O OH PPi O P OH O O CH 2 O OH PPi + Base (ie Adenine) + A

22. Purines in humans are degraded to Urate 1. Nucleotides are constantly undergoing turnover! 2. There are many enzymes involved; Nucleotidases Nucleoside phosphorylases Deaminases Xanthine oxidases 3. the final common intermediate in humans is Urate, which is excreted. 4. there are several metabolic disorders resulting from defects in purine catabolism.

23. Catabolism of Purine Nucleotides

24. Disorders of Purine Metabolism: DisorderDefect Comments Gout PRPP synthase/ Hyperuricemia HGPRT Lesch Nyhanlack of HGPRT Hyperuricemia syndrome SCID ADA High levels of dAMP von Gierke’s diseaseglucose -6-PTPase Hyperuricemia

25.  a disorder associated with abnormal amounts of urates in the body  early stage: recurring acute non-articular arthritis  late stage: chronic deforming polyarthritis and eventual renal complication  disease with rich history dating back to ancient Greece

26. Ribose 5-phosphate PRPP Phosphoribosyl amine IMP AMP GMP Inhibited by IMP, AMP, and GMP Inhibited by AMP Inhibited by GMP What happens in gout? 1. Negative regulation of PRPP Synthatase & PRPP Amidotransferase is lost 2. PRPP levels are increased because of defects in salvage pathways Therefore, there is net increase in biosynthetic/degradation pathways!!

27. GOUT (Gouty Arthritis): A defect of purine metabolism Serum Uric Acid Levels (mg/dl) Incidence of Gout (% of cases) Incidence of Gout (% of cases) >9.0 ~10% 7-9 0.5-3.5% <7.0 0.1% Guanine Xanthine Hypoxanthine Urate xanthine oxidase Allopurinol: a. decrease urate b. increase xanthine & hypoxanthine c. decrease PRPP Allopurinol: a. decrease urate b. increase xanthine & hypoxanthine c. decrease PRPP

28.  prevails mainly in adult males  rarely encountered in premenopausal women  symptoms are cause by deposition of crystals of monosodium urate monohydrate (can be seen under polarized light)  usually affect joints in the lower extremities (the big toe is the classic site)

30. SCID-Severe Combined Immunodeficiency Syndrome AMP Adenosine Inosine H20H20 Pi H20H20 NH 3 Hypoxanthine Nucleotidase Adenine deaminase* Autosomal recessive disorder Mutations in ADA Infants subject to bacterial, candidiasis, viral, protazoal infections Both T and B cells are significantly reduced (dATP is toxic) 1995-AdV expressing ADA was successfully employed as gene therapy strategy Autosomal recessive disorder Mutations in ADA Infants subject to bacterial, candidiasis, viral, protazoal infections Both T and B cells are significantly reduced (dATP is toxic) 1995-AdV expressing ADA was successfully employed as gene therapy strategy

31. Degradation of AMP

33.  In the absence of ADA lymphocytes are destroyed  deoxyadenosine is not destroyed, is converted to dAMP and then into dATP  dATP is a potent feedback inhibitor of deoxynucleotide biosynthesis  this leads to SCID (severe combined immunodeficiency disease)  Infants with this deficiency have a high fatality rate due to infections

34.  treatment consists of administering pegylated ADA which can remain in the blood for 1 – 2 weeks  more efficient is gene therapy: replacing the gene that is missing or defective  gene therapy has been performed on selected patients

35. Degradation of GMP and XMP

36. http://www.wiley.com/college/fob/q uiz/quiz22/quizzer22.html Please, Send the online Quiz to my email; ggawish@ksu.edu.sa